Director, Portfolio Strategy Inflammation & Immunology

Use Your Power for Purpose

Everything we do, every day, is driven by an unwavering commitment to the patients, healthcare providers, and customers who depend on us. In Global Commercial Strategy (GCS), we translate science of R&D into value for patients and Pfizer - from early development through launch, growth, and LOE lifecycle. GCS serves as the strategic engine and commercial voice across the asset lifecycle - shaping asset positioning and evidence generation, leading global launches, and driving sustained access and brand performance through market and payer insights, broad access, & commercial rigor.

We take pride in shaping how innovative medicines reach the people who need them most, and ensuring they are accessible, understood, and valued across every market. Our success is anchored in the following Pfizer Blueprint values:
Science, Technology, Transformation and Colleagues. Whether you are defining strategy, managing brands at different lifecycle, or building the capabilities that power our commercial engine, your work directly shapes patient outcomes and the long‑term success of Pfizer's portfolio.

The Director, Portfolio Strategy is an individual contributor role within the Inflammation & Immunology (I&I) Early Commercial Business, part of the Global Commercial Strategy organization, reporting to the I&I Portfolio Strategy & Disease Area Lead ("DAL"). This role is responsible for developing and supporting portfolio strategy, early commercial assessments, and investment decision support across the I&I pipeline. The colleague will bring strong strategic judgment, analytical rigor, and scientific curiosity to help shape portfolio priorities, product concepts, and differentiated commercial opportunities across autoimmune and inflammatory diseases.

The broader I&I and Rare Disease portfolio represents significant strategic value to realizing Pfizer's vision to achieve leadership via breakthroughs in prioritized diseases and biological axes, with the goal of generating highly differentiated, multi‑indication mega‑blockbusters. Today, the portfolio delivers more than $10B globally, with 22 ongoing clinical studies underway to significantly expand the product portfolio over the next several years. This role will contribute to that ambition by helping shape I&I portfolio strategy and early commercial decision‑making across high‑value pipeline and lifecycle opportunities.

The Director will partner closely with R&D, Medical Affairs, Global Access Strategy & Pricing (GASP), Business Analytics & Insights, Competitive Intelligence, Business Development, and US and International Commercial teams to translate scientific, clinical, market, access, and competitive insights into clear portfolio recommendations. This role is focused on early commercial strategy and portfolio decision‑making. The Director will help advance disciplined trade‑off decisions, long‑range portfolio thinking, and AI‑enabled ways of working that support patient impact and enterprise value realization for the I&I portfolio.

I&I Portfolio Strategy and Long‑Range Planning:

• Support development of long‑range commercial and portfolio strategy for the I&I Early Commercial Business, spanning early pipeline assets, lifecycle opportunities, and emerging disease areas.

• Synthesize scientific, clinical, commercial, access, competitive, and patient insights to inform portfolio priorities and strategic trade‑offs.

• Assess opportunities across near-, mid-, and long‑term horizons to identify areas of differentiated value creation for Pfizer's I&I portfolio.

• Translate portfolio strategy into clear recommendations, implications, and decision materials for leadership and governance discussions.

• Monitor shifts in the I&I scientific and competitive landscape to identify emerging trends, risks, and potential development opportunities.

Early Commercial Assessment and Product Concept Development:

• Develop and refine early commercial assessments for I&I pipeline assets, indications, mechanisms, and disease‑area opportunities.

• Support development of product concepts, target product profile input, positioning hypotheses, market…